E David Crawford

Summary

Publications

  1. ncbi request reprint Screening for prostate cancer: current recommendations
    Shandra S Wilson
    Department of Urologic Oncology, Anschutz Cancer Center, 1665 North Ursula, Aurora, CO 80010, USA
    Urol Clin North Am 31:219-26. 2004
  2. ncbi request reprint Controversies regarding screening for prostate cancer
    E David Crawford
    Department of Urologic Oncology, University of Colorado, Denver, CO 80010, USA
    BJU Int 100:5-7. 2007
  3. doi request reprint Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies
    E David Crawford
    Department of Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, Colorado Electronic address
    J Urol 194:1537-47. 2015
  4. doi request reprint Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl
    E David Crawford
    a 1 University of Colorado Cancer Center, University of Colorado Health Sciences Center, Urologic Oncology Department, Mail Stop F710, 1665 N Ursula Street, Rm 1004, P O Box 6510, Aurora, CO 80045, USA 1 720 848 0195 1 720 848 0203
    Expert Opin Drug Metab Toxicol 11:1465-74. 2015
  5. doi request reprint Challenges and recommendations for early identification of metastatic disease in prostate cancer
    E David Crawford
    University of Colorado, Denver Aurora, CO Electronic address
    Urology 83:664-9. 2014
  6. doi request reprint Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial
    Thomas W Flaig
    Department of Medicine, University of Colorado Health Science Center, Mail Stop 8117, P O Box 6511, Aurora, CO 80045 0511, USA
    J Clin Oncol 26:1532-6. 2008
  7. pmc The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer
    Al B Barqawi
    Department of Surgery, Urologic Oncology, Anschutz Campus, Aurora, CO 80045, USA
    Int J Clin Exp Pathol 4:468-75. 2011
  8. pmc Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume
    Priya N Werahera
    Department of Pathology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045, USA
    Int J Clin Exp Pathol 5:892-9. 2012
  9. doi request reprint Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix
    E David Crawford
    Department of Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, CO Electronic address
    Urology 83:1122-8. 2014
  10. ncbi request reprint Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial
    M Scott Lucia
    Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B 216, Denver, CO 80262, USA
    J Natl Cancer Inst 99:1375-83. 2007

Detail Information

Publications113 found, 100 shown here

  1. ncbi request reprint Screening for prostate cancer: current recommendations
    Shandra S Wilson
    Department of Urologic Oncology, Anschutz Cancer Center, 1665 North Ursula, Aurora, CO 80010, USA
    Urol Clin North Am 31:219-26. 2004
    ..It is hoped that prospective, randomized, long-term screening studies, such as the PLCO and ERSCP trials, will show improved survival using the admittedly imperfect PSA marker in prostate cancer screening...
  2. ncbi request reprint Controversies regarding screening for prostate cancer
    E David Crawford
    Department of Urologic Oncology, University of Colorado, Denver, CO 80010, USA
    BJU Int 100:5-7. 2007
  3. doi request reprint Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies
    E David Crawford
    Department of Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, Colorado Electronic address
    J Urol 194:1537-47. 2015
    ....
  4. doi request reprint Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl
    E David Crawford
    a 1 University of Colorado Cancer Center, University of Colorado Health Sciences Center, Urologic Oncology Department, Mail Stop F710, 1665 N Ursula Street, Rm 1004, P O Box 6510, Aurora, CO 80045, USA 1 720 848 0195 1 720 848 0203
    Expert Opin Drug Metab Toxicol 11:1465-74. 2015
    ..Recent studies have demonstrated that a T level as low as 20 ng/dl may produce improved clinical outcomes...
  5. doi request reprint Challenges and recommendations for early identification of metastatic disease in prostate cancer
    E David Crawford
    University of Colorado, Denver Aurora, CO Electronic address
    Urology 83:664-9. 2014
    ..The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer. ..
  6. doi request reprint Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial
    Thomas W Flaig
    Department of Medicine, University of Colorado Health Science Center, Mail Stop 8117, P O Box 6511, Aurora, CO 80045 0511, USA
    J Clin Oncol 26:1532-6. 2008
    ..Southwest Oncology Group (SWOG) study 9921 is a randomized, phase III, intergroup study to define the role of adjuvant chemotherapy in patients with high-risk prostate cancer...
  7. pmc The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer
    Al B Barqawi
    Department of Surgery, Urologic Oncology, Anschutz Campus, Aurora, CO 80045, USA
    Int J Clin Exp Pathol 4:468-75. 2011
    ....
  8. pmc Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume
    Priya N Werahera
    Department of Pathology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045, USA
    Int J Clin Exp Pathol 5:892-9. 2012
    ..Thus, we recommend performing MB, MFSB, and TZB based on prostate volume, as follows: 8 biopsies for ≤15 cc; 14 for those >15 cc but ≤50 cc, and 14-20 for those >50 cc...
  9. doi request reprint Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix
    E David Crawford
    Department of Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, CO Electronic address
    Urology 83:1122-8. 2014
    ..To demonstrate the safety and efficacy of up to 5 years of degarelix treatment and the effects of crossing over from leuprolide to degarelix in the extension phase of a phase III pivotal 1-year trial...
  10. ncbi request reprint Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial
    M Scott Lucia
    Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B 216, Denver, CO 80262, USA
    J Natl Cancer Inst 99:1375-83. 2007
    ..We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride's potential effects on tumor morphology or prostate size...
  11. pmc Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens
    E David Crawford
    Division of Urology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA
    Prostate 73:778-87. 2013
    ....
  12. doi request reprint Role of testosterone in managing advanced prostate cancer
    Kyle O Rove
    University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
    Urology 80:754-62. 2012
    ..Incorporating this information, we have made recommendations incorporating testosterone evaluation and its effect on the clinical decision-making process...
  13. ncbi request reprint The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
    Ali Ziada
    UCHSC, 4200 E 9th Ave C 319, Denver, CO, USA
    Prostate 60:332-7. 2004
    ..To investigate the efficacy and toxicity of the antibody to the HER-2/neu receptor (trastuzumab, Herceptin) in the treatment of advanced hormone-refractory prostate cancer (HRPC)...
  14. doi request reprint The benefits of early androgen blockade
    Paul D Maroni
    The University of Colorado at Denver and Health Sciences Center, Academic Office One Bldg, Aurora, CO 80045, USA
    Best Pract Res Clin Endocrinol Metab 22:317-29. 2008
    ..This review concentrates on high-level evidence to address common clinical situations in advanced and metastatic prostate cancer. Additionally, the side-effects of androgen blockade have become increasingly visible and relevant...
  15. doi request reprint The utility of prostate-specific antigen in the management of advanced prostate cancer
    E David Crawford
    University of Colorado School of Medicine, Aurora, CO, USA
    BJU Int 112:548-60. 2013
    ....
  16. doi request reprint Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, 80045, USA
    BJU Int 108:1743-9. 2011
    ..This study examines a larger number of men in a diverse US population to determine the prognostic value of a man's baseline or first PSA...
  17. doi request reprint Validation of the modified American Urological Association symptom score
    E David Crawford
    Department of Surgery, University of Colorado Denver, School of Medicine, Aurora, Colorado 80045, USA
    J Urol 186:945-8. 2011
    ..We created a shorter version of the American Urological Association symptom score, called UWIN (urgency, weak stream, incomplete emptying and nocturia)...
  18. ncbi request reprint Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy
    Al Baha Barqawi
    Division of Urology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:872-6. 2003
    ..To evaluate the efficacy and tolerability of combined finasteride and low-dose flutamide for prostate-specific antigen (PSA)-only recurrence after definitive therapy and to determine the predictors of recurrence-free survival...
  19. ncbi request reprint High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade
    Zinelabidine Abouelfadel
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Prostate Cancer 1:115-7. 2002
    ..Continued screening for prostate cancer is resulting in the diagnosis of more unfavorable cancers...
  20. ncbi request reprint A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer
    Thomas W Flaig
    Department of Medicine, University of Colorado Health Sciences Center, Aurora, CO 80045 0511, USA
    Cancer 107:266-74. 2006
    ..Preclinical data from prostate cancer cell lines suggested a synergistic effect of these therapies...
  21. pmc Anterior tumors of the prostate: diagnosis and significance
    Priya N Werahera
    University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA
    Can J Urol 20:6897-906. 2013
    ..Consequently, tumors originating from the anterior apical region and transition zones may be under-sampled. We examined whether addition of transrectal anterior biopsy (TAB) would improve efficacy of prostate biopsies...
  22. ncbi request reprint Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy
    E David Crawford
    Radiation Oncology, Department of Pathology, University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO 80045, USA
    BJU Int 96:999-1004. 2005
    ..To identify the precise location of prostate cancer within the gland and thus possibly permit more aggressive therapy of the lesion, while potentially sparing the noncancerous gland from ablative therapy...
  23. ncbi request reprint Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival
    Kyle O Rove
    Section of Urologic Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA
    Oncology (Williston Park) 25:1362-70, 1375-81, 1387. 2011
    ....
  24. ncbi request reprint Recent advances in hormonal therapy for advanced prostate cancer
    Siam Oottamasathien
    Department of Surgery, Division of Urology, University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 17:1047-52; discussion 1054-8. 2003
    ..Although hormonal therapy is an important treatment modality for advanced prostate cancer, long-term treatment carries significant side effects that need to be considered...
  25. doi request reprint Methods of developing UWIN, the modified American Urological Association symptom score
    Al B Barqawi
    Department of Surgery, University of Colorado Denver, School of Medicine, Aurora, Colorado 80045, USA
    J Urol 186:940-4. 2011
    ..We describe the methods used to develop a shorter form of the American Urological Association symptom score that may provide symptom score assessment with minimal compromise in accuracy...
  26. ncbi request reprint Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo
    E David Crawford
    University of Colorado Health Sciences Center, Aurora, Colorado, USA
    J Urol 175:1422-6; discussion 1426-7. 2006
    ..We analyzed data from the placebo arm of the MTOPS trial to determine clinical predictors of BPH progression...
  27. ncbi request reprint The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms
    Al Baha Barqawi
    Urologic Oncology Department, School of Medicine, University of Colorado Health Science Center, Denver, Colorado, USA
    BJU Int 100:853-7. 2007
    ..To assess the effect of tamsulosin on the Sexual Health Inventory for Men (SHIM) score in men diagnosed with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)...
  28. doi request reprint The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study
    Chad G Rusthoven
    Department of Radiation Oncology, University of Colorado Denver, Aurora, Colorado Electronic address
    Int J Radiat Oncol Biol Phys 88:1064-73. 2014
    ....
  29. pmc Maximal testosterone suppression in prostate cancer--free vs total testosterone
    Kyle O Rove
    Division of Urology, University of Colorado, Anschutz Medical Campus, Aurora, CO Electronic address
    Urology 83:1217-22. 2014
    ..Free testosterone may better reflect prostate cancer tissue androgen levels than serum total testosterone concentration. Free testosterone deserves more research regarding its relation to clinical outcomes. ..
  30. ncbi request reprint Prostate cancer in a man with multiple previous cancers
    Thomas Flaig
    University of Colorado, Health Sciences Center, Aurora, Colorado, USA
    Oncology (Williston Park) 21:611-4. 2007
  31. ncbi request reprint Screening for prostate cancer
    Shandra S Wilson
    Department of Urologic Oncology, Anschutz Cancer Center, Denver, CO, USA
    Clin Prostate Cancer 3:21-5. 2004
    ..These measures include prevention, screening, improved curative treatment, and the transformation of an acute lethal disease to a chronic, tolerable one. This summary focuses on the screening aspects of prostate cancer...
  32. ncbi request reprint Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer
    E David Crawford
    University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 21:27-32; discussion 33-4, 39. 2007
    ..In this review, we present the current status of our knowledge about this procedure and the most important challenges that need to be addressed. We also present the initial results with this approach at our center...
  33. doi request reprint A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer
    Thomas W Flaig
    Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA
    Prostate 70:848-55. 2010
    ..The purpose of the current trial was to determine the tissue and blood effects of high-dose silybin-phytosome in prostate cancer patients...
  34. ncbi request reprint Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program
    Al Baha Barqawi
    Section of Urologic Oncology, University of Colorado Health Science Center School of Medicine, Denver, Colorado, USA
    Urology 65:708-12. 2005
    ..To assess the effect of aging and body mass index (BMI) on both serum total prostate-specific antigen (tPSA) and complexed PSA (cPSA) from the results of the 2003 Prostate Cancer Awareness Week national screening database...
  35. pmc Comorbidity and mortality results from a randomized prostate cancer screening trial
    E David Crawford
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Clin Oncol 29:355-61. 2011
    ..However, results analyzed by comorbidity strata remain unknown...
  36. ncbi request reprint Herbal and vitamin supplement use in a prostate cancer screening population
    Albaha Barqawi
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 63:288-92. 2004
    ....
  37. doi request reprint The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions
    Natalie J Serkova
    Department of Anesthesiology and Radiology, Biomedical MRI MRS, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Prostate 68:620-8. 2008
    ..In this study, proton nuclear magnetic resonance spectroscopy ((1)H-NMRS) is used to assess potential metabolic markers of prostate cancer (PCa) in human expressed prostatic secretions (EPS)...
  38. ncbi request reprint Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile
    E David Crawford
    University of Colorado Health Sciences Center, Aurora, Colorado 80010, USA
    BJU Int 95:1-5. 2005
  39. ncbi request reprint The association of time of day and serum testosterone concentration in a large screening population
    E David Crawford
    Surgery and Radiation Oncology, Section of Urologic Oncology, UCHSC, Aurora, CO, USA
    BJU Int 100:509-13. 2007
    ....
  40. pmc Proliferative tumor doubling times of prostatic carcinoma
    Priya N Werahera
    Department of Pathology, University of Colorado Anschutz Medical Campus, P O Box 6511, Aurora, CO 80045, USA
    Prostate Cancer 2011:301850. 2011
    ..While lack of data for apoptotic rates is a limitation, apparent biological differences between latent versus aggressive PCa may be attributable to variations in apoptotic rates of these tumors rather than their cell proliferative rates...
  41. ncbi request reprint Surgical management of prostate cancer: optimizing patient selections and clinical outcome
    Paul D Maroni
    Division of Urology, Department of Surgery, University of Colorado Health Sciences Center, Denver, 80252, USA
    Surg Oncol Clin N Am 14:301-19. 2005
  42. doi request reprint Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer
    Kyle O Rove
    University of Colorado, Anschutz Medical Campus, Division of Urology, Aurora, CO 80045, USA
    Curr Opin Urol 23:208-13. 2013
    ..New US Food and Drugs Administration approved pharmaceutical agents further eliminate testosterone ligand or its activity via inhibition of key synthetic enzymes and through strong inhibition of the androgen receptor...
  43. ncbi request reprint Preventing and treating the complications of hormone therapy
    Ravi J Kumar
    Urologic Oncology, University of Colorado Health Sciences Center, 4200 East 9th Avenue C 319, Denver, CO 80262, USA
    Curr Urol Rep 6:217-23. 2005
    ....
  44. ncbi request reprint Intermediate- to high-risk prostate cancer patient treated with radiation therapy
    E David Crawford
    University of Colorado Health Sciences Center, Denver, USA
    Oncology (Williston Park) 18:1105-10. 2004
  45. ncbi request reprint Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:13-9. 2003
    ....
  46. doi request reprint Targeted focal therapy for prostate cancer: a review
    Amy H Hou
    University of Colorado Health Sciences Center, Department of Urology, Aurora, Colorado 80045, USA
    Curr Opin Urol 19:283-9. 2009
    ..In this review, we will discuss targeted focal therapy (TFT) using the modalities of cryotherapy or high intensity focused ultrasound as an alternate treatment for low-risk prostate cancers...
  47. doi request reprint The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer
    Al B Barqawi
    Division of Urology, University of Colorado Denver, Aurora, Colorado, USA
    J Urol 186:80-5. 2011
    ..We determined the impact of a grid based, transperineal 3-dimensional mapping biopsy on decision making for primary management of early stage prostate cancer...
  48. ncbi request reprint Metastatic cancer in solid tumors and clinical outcome: skeletal-related events
    Kyle O Rove
    University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA
    Oncology (Williston Park) 23:21-7. 2009
    ....
  49. pmc Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial
    E David Crawford
    Section of Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, Colorado, USA
    J Urol 186:965-70. 2011
    ..We conducted a 2-stage, multicenter, double-blind, randomized phase II clinical trial of 100 and 300 unit doses of onabotulinum toxin A to treat the lower urinary tract symptoms of benign prostatic hyperplasia...
  50. ncbi request reprint Screening for prostate cancer in 2006: PSA in the 21st century
    Paul D Maroni
    Division of Urology, Department of Surgery, University of Colorado Health Sciences Center, USA
    N C Med J 67:136-9. 2006
  51. ncbi request reprint Minimally invasive surgery in prostate cancer: current and future perspectives
    Bulent Akduman
    University of Colorado Health Sciences Center, Anschutz Cancer Pavillion, Aurora, Colorado 80010, USA
    Cancer J 11:355-61. 2005
    ..In this review we critically discuss the current knowledge and future perspectives of minimally invasive treatment in prostate cancer...
  52. ncbi request reprint A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    J Urol 175:533-6. 2006
    ..The safety, efficacy and pharmacokinetics of LA-2585, a new 6-month subcutaneous depot of leuprolide acetate (Atrix Laboratories, Fort Collins, Colorado) were investigated in patients with prostate cancer...
  53. ncbi request reprint PSA testing: what is the use?
    E David Crawford
    University of Colorado, Denver, CO 80262, USA
    Lancet 365:1447-9. 2005
  54. ncbi request reprint The current use and future trends of focal surgical therapy in the management of localized prostate cancer
    Al B Barqawi
    Urologic Oncology Department, School of Medicine, University of Colorado Health Science Center, Denver, CO, USA
    Cancer J 13:313-7. 2007
    ..In addition, we will discuss future promising tools in MIT such as photodynamic therapy and the target focal therapy approach as a new trend for the treatment of organ-confined low-volume disease...
  55. ncbi request reprint Artificial neural networks for predictive modeling in prostate cancer
    Eduard J Gamito
    University of Colorado Health Sciences Center, C 314, 200 East 9th Avenue, Denver, CO 80262, USA
    Curr Oncol Rep 6:216-21. 2004
    ..This article provides an overview of the theoretical basis of ANNs, how they function, their strengths and limitations, and examples of how ANNs have been used to develop predictive models for the management of prostate cancer...
  56. doi request reprint Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts
    Kyle O Rove
    Division of Urology, University of Colorado, Anschutz Medical Campus, Mail Stop F710, P O Box 6510, Aurora, CO 80045, USA
    World J Urol 30:137-42. 2012
    ..This report aims to clarify the issues specific to the PSA test, prostate cancer, sources of bias, and the future of screening...
  57. ncbi request reprint Prostate cancer chemoprevention: an overview of United States trials
    Albaha Barqawi
    Division of Urologic Oncolgy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Urol 171:S5-8; discussion S9. 2004
    ..We review the current status of clinical trials investigating the use of interventions designed to reduce the risk of prostate cancer...
  58. ncbi request reprint Controversies of androgen ablation therapy for metastatic prostate cancer
    Shandra S Wilson
    Department of Urologic Oncology, 1665 North Ursula, Aurora, CO 80010, USA
    Curr Pharm Des 12:799-805. 2006
    ....
  59. ncbi request reprint The role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Am J Clin Oncol 29:517-23. 2006
    ..This review will analyze the current state of knowledge of LUTS secondary to RT for prostate cancer and review treatment options for this complication...
  60. doi request reprint A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer
    E David Crawford
    Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, Colorado 80045, USA
    J Urol 186:889-97. 2011
    ..We investigated the efficacy and safety of degarelix treatment and the effects of switching from leuprolide to degarelix in an ongoing extension study with a median 27.5-month followup of a pivotal 1-year prostate cancer trial...
  61. ncbi request reprint Three different strategies for real-time prostate capsule volume computation from 3-D end-fire transrectal ultrasound
    Albaha B Barqawi
    University of Colorado Health Science Center, Aurora, CO 80010, USA
    Conf Proc IEEE Eng Med Biol Soc 2007:816-8. 2007
    ..The mean volumes using the least square, level set and DDC techniques were 15.84 cc, 15.55 cc and 16.33 cc, respectively. We validated the methods by calculating the volume with GT and we got an average volume of 15...
  62. doi request reprint Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, Colorado 80045, USA
    J Urol 188:1726-31. 2012
    ..We investigated the value of the PCA3 (prostate cancer gene 3) urine test in predicting the likelihood of diagnosis of cancer before biopsy...
  63. ncbi request reprint Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma
    Thomas D Denberg
    University of Colorado at Denver and Health Sciences Center, Denver, CO, USA
    BJU Int 98:335-40. 2006
    ....
  64. doi request reprint Understanding the epidemiology, natural history, and key pathways involved in prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Science Center, Denver, Colorado, USA
    Urology 73:S4-10. 2009
    ..A substantial research effort has recently focused on understanding the pathways involved in the disease's emergence and progression, particularly the 5alpha-reductase pathway...
  65. ncbi request reprint Focal therapy in prostate cancer: future trends
    Al Barqawi
    University of Colorado Health Sciences Center, 4200 E 9th Ave, C 319, Denver, Colorado 80262, USA
    BJU Int 95:273-4. 2005
  66. doi request reprint PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Eur Urol 54:262-73. 2008
    ..Despite the substantive societal impact of prostate cancer, the medical community is currently divided on the balance between benefit and harm of screening for prostate cancer using prostate-specific antigen (PSA)...
  67. ncbi request reprint Should routine screening for prostate-specific antigen be recommended?
    Siam Oottamasathien
    Division of Urology, Box c319, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
    Arch Intern Med 163:661-2; discussion 666. 2003
  68. ncbi request reprint Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models
    Priya N Werahera
    Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Hum Pathol 35:798-807. 2004
    ..Moreover, our 3-dimensional computer modeling system improves upon other systems: It is more than a simple extension of the planimetric technique, and it is able to demarcate clearly the boundaries of Gleason grades just 1 grade apart...
  69. ncbi request reprint Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
    L Michael Glode
    Oncology Urology Department, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer 98:1643-8. 2003
    ....
  70. ncbi request reprint Early versus late hormonal therapy: debating the issues
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center, Denver, Colorado 80010, USA
    Urology 61:8-13. 2003
    ..Thus, accumulating evidence provides a rationale for continued investigation into the use of early hormonal therapy in selected patients...
  71. ncbi request reprint The management of high risk prostate cancer
    Bulent Akduman
    Section of Urologic Oncology, Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Urol 169:1993-8. 2003
    ..There is no consensus on the treatment of these groups of patients. The role of radiotherapy, hormonal therapy or chemotherapy must be defined...
  72. ncbi request reprint Epidemiology of prostate cancer
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:3-12. 2003
    ..In contrast, mortality rates for men diagnosed with localized or regional disease increased gradually during most of the 1990s before decreasing slightly among white men and reaching plateaus among African Americans...
  73. ncbi request reprint Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, Washington, DC, USA
    J Urol 175:1286-90; discussion 1290. 2006
    ..A large fraction of screened men have low (less than 2 ng/ml) initial PSA. The yield over time of positive PSA screens (ie more than 4 ng/ml) in these men has not been well characterized in large cohorts in the United States...
  74. ncbi request reprint A 42-year-old woman with breast cancer
    E David Crawford
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 17:614; discussion 615-20. 2003
    ..At this point, we recommend tamoxifen, with consideration to adding goserelin (Zoladex) if the patient does not remain amenorrheic. The patient chose to enter the Intergroup trastuzumab trial...
  75. ncbi request reprint Genitourinary malignancies
    Shandra S Wilson
    Department of Urologic Oncology, Anschuz Cancer, Aurora, CO 80010, USA
    Cancer Chemother Biol Response Modif 22:485-513. 2005
  76. doi request reprint Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Urology 75:502-9. 2010
    ..Particular emphasis is placed on the design of the second large-scale trial of a 5alpha-reductase inhibitor, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial...
  77. ncbi request reprint Emerging role of HIFU as a noninvasive ablative method to treat localized prostate cancer
    Al B Barqawi
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurura, CO 80010, USA
    Oncology (Williston Park) 22:123-9; discussion 129, 133, 137 passim. 2008
    ..This review summarizes current knowledge about the basic principles of HIFU and its reported efficacy and morbidity in clinical series published since 2000...
  78. ncbi request reprint Prostate cancer. Introduction
    E David Crawford
    Division of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:1-2. 2003
  79. ncbi request reprint A 72-year-old man with prostate cancer
    E David Crawford
    University of Colorado Health Sciences Center, Denver, USA
    Oncology (Williston Park) 16:1014-6, 1119-21. 2002
  80. ncbi request reprint Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor
    Lin Qi
    Department of Medicine, Division of Medical Oncology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Cancer Res 64:2090-5. 2004
    ..It may also be useful as a therapeutic agent to eliminate pituitary gonadotrophs, eliminating the need for chronic GnRH analogue administration to treat hormone-sensitive diseases...
  81. ncbi request reprint SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study
    Catherine E Klein
    University of Colorado, Denver, Colorado, USA
    Prostate 52:264-8. 2002
    ..Topotecan is a new topoisomerase-1 inhibitor whose early investigation suggested possible activity in hormone-refractory prostate cancer...
  82. ncbi request reprint My total prostate-specific antigen (PSA) level is 0.2 nanograms per milliliter, which I'm told is normal. But my free-to-total PSA ratio is 8 percent, which I've read indicates a high risk of prostate cancer. What do these seemingly contradictory PSA resu
    E David Crawford
    University of Colorado, Health Sciences Center, Aurora, Colorado, USA
    Health News 9:12. 2003
  83. ncbi request reprint Is a screening interval of every 4 years for prostate cancer acceptable?
    E David Crawford
    J Natl Cancer Inst 99:1279-80. 2007
  84. ncbi request reprint Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial
    Gerald L Andriole
    Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
    J Natl Cancer Inst 97:433-8. 2005
    ..We describe the population enrolled in the PLCO trial, their baseline PSA and DRE screening results, and diagnostic follow-up results during the first year of follow-up...
  85. ncbi request reprint Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA
    BJU Int 99:775-9. 2007
    ..To determine patterns of repeat prostate biopsy in a cohort of men undergoing prostate cancer screening who have a negative initial biopsy...
  86. ncbi request reprint Prostate-specific antigen velocity and prostate cancer gleason grade and stage
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer 109:1689-95. 2007
    ..The authors evaluated the relation between PSAV, biopsy Gleason score, and pathologic stage in men who were enrolled in a prostate cancer screening trial...
  87. ncbi request reprint Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, MC 7845, 7703 Floyd Curl Dr, San Antonio, TX 78229 3900, USA
    JAMA 296:2329-35. 2006
    ..However, the optimal management of these patients after radical prostatectomy is unknown...
  88. ncbi request reprint Metastatic prostate cancer-does treatment of the primary tumor matter?
    Gregory Swanson
    Department of Radiation Oncology, University of Texas Health Science Center at San Antonio and Cancer Therapy and Research Center, San Antonio, Texas, 78229 3900, USA
    J Urol 176:1292-8. 2006
    ..We reviewed the effect of treating the principal disease bulk on overall treatment outcome in patients with advanced and metastatic cancer. Specifically we evaluated the role of surgical tumor cytoreduction...
  89. ncbi request reprint Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia
    James R Marshall
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Epidemiol Biomarkers Prev 15:1479-84. 2006
    ..Subject accrual is expected to be completed by the fall of 2006, with trial completion in 2009...
  90. ncbi request reprint Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)
    Maha Hussain
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 24:3984-90. 2006
    ..To establish whether absolute prostate-specific antigen (PSA) value after androgen deprivation (AD) is prognostic in metastatic (D2) prostate cancer (PCa)...
  91. pmc Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)
    A Oliver Sartor
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 112:2393-400. 2008
    ..This study was designed to examine antiandrogen withdrawal effects within the context of a large multi-institutional prospective trial...
  92. ncbi request reprint Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024
    Gregory P Swanson
    University of Texas Health Science Center, San Antonio, USA
    J Urol 176:548-53; discussion 553. 2006
    ..Studies have shown that adding androgen ablation improves the results but there is still much room for improvement. We performed a phase II multi-institutional study to explore the feasibility of concomitant chemoradiotherapy...
  93. ncbi request reprint Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove
    Abraham Morgentaler
    J Urol 175:1572; author reply 1573-4. 2006
  94. ncbi request reprint Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer
    Dominique S Michaud
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 66:4525-30. 2006
    ..At least seven common polymorphisms in genes of inflammatory cytokines IL-1B, IL-6, IL-8, and IL-10 do not seem to play a role in the risk of prostate cancer...
  95. ncbi request reprint Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning
    Tracy R Glass
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Urol 169:164-9. 2003
    ..Risk stratification is helpful for designing clinical trials and individual treatment, and it should be incorporated into future reports of outcomes of patients with metastatic disease...
  96. ncbi request reprint Predicting the outcome of prostate biopsy in a racially diverse population: a prospective study
    Christopher R Porter
    Department of Urology, State University of New York, Stony Brook, New York, USA
    Urology 60:831-5. 2002
    ..To develop a mathematical model to predict prostate biopsy outcome using readily available clinical variables...
  97. ncbi request reprint Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
    Daniel P Petrylak
    Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 98:516-21. 2006
    ..We evaluated PSA changes as potential surrogate markers for survival by using data from a clinical trial...
  98. ncbi request reprint Bone metabolism and new targets for intervention
    Bulent Akduman
    Department of Urology, School of Medicine, Zonguldak Karaelmas University, Zonguldak, Turkey
    Curr Urol Rep 8:233-8. 2007
    ..In addition to traditional treatment approaches, targeted therapy is currently becoming more popular. Bone metabolism, metastatic processes of prostate cancer, and the targeting of treatment for advanced disease are discussed here...
  99. ncbi request reprint A prospective study of lycopene and tomato product intake and risk of prostate cancer
    Victoria A Kirsh
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 15:92-8. 2006
    ..Dietary lycopene and tomato products may reduce risk of prostate cancer; however, uncertainty remains about this possible association...
  100. ncbi request reprint The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer
    Marileila Varella-Garcia
    University of Colorado Comprehensive Cancer Center, UCHSC, Denver CO, USA
    Urol Oncol 22:16-9. 2004
    ....
  101. ncbi request reprint Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting
    Christopher R Porter
    Section of Urology and Renal Transplantation, Virginia Mason Medical Center, Seattle, Washington 98111, USA
    Urology 65:937-41. 2005
    ..To develop a model capable of predicting prostate biopsy outcomes in a large screening population, with independent validation in the referral setting...